| 1 |
Kane SF. Bone tumors: multiple myeloma[J]. FP Essent, 2020，493：30-35.
|
| 2 |
Cowan AJ, Tuazon SA, Poruguese AJ, et al. Chimeric antigen receptor T Cells for multiple myeloma：The journey so far and the road ahead[J]. Cancer J, 2021，27(2)：112-118.
|
| 3 |
Pulte D, Jansen L, Brenner H. Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century[J]. Blood Cancer J, 2020, 10(5): 56.
|
| 4 |
Choi T, Kang Y. Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma[J]. Pharmacol Ther, 2022, 232: 108007.
|
| 5 |
中国医师协会血液科医师分会，中华医学会血液学分会．嵌合抗原受体T细胞治疗多发性骨髓瘤中国血液临床专家共识(2022年版)[J]．中华血液学杂志，2022, 43(4)：265-271.
|
| 6 |
Song EZ, Milone MC. Pharmacology of chimeric antigen receptor-modified T cells[J]. Annu Rev Pharmacol Toxicol, 2021，61：805-829.
|
| 7 |
Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity[J]. Proc Natl Acad Sci U S A, 1989，86(24)：10024-10028.
|
| 8 |
Stock S, Schmitt M, Sellner L. Optimizing manufacturing protocols of chimeric antigen receptor T cells for improved anticancer immunotherapy[J]. Int J Mol Sci, 2019，20(24)：6223.
|
| 9 |
Liu Q, Li J, Zheng H, et al. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T[J]. Mol Cancer, 2023, 22(1)：28.
|
| 10 |
Zhang P, Zhang G, Wan X. Challenges and new technologies in adoptive cell therapy[J]. J Hematol Oncol, 2023, 16(1)：97.
|
| 11 |
Sun W, Liang AB, Huang H, et al. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience[J]. Haematologica, 2023，108(8)：2011-2028.
|
| 12 |
Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study[J]. Lancet, 2020, 396(10254): 839-852.
|
| 13 |
Pan J, Yang JF, Deng BP, et al. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients[J]. Leukemia, 2017, 31(12)：2587-2593.
|
| 14 |
Zhang X, Lu XA, Yang J, et al. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features[J]. Blood Adv, 2020, 4(10): 2325-2338.
|
| 15 |
AnagnostouT, RiazIB, HashmiSK, et al. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis[J]. Lancet Haematol, 2020, 7(11): e816-e826.
|
| 16 |
Pasvolsky O, Kebriaei P, Shah BD, et al. Chimeric antigen receptor T-cell therapy for adult B-cell acute lymphoblastic leukemia: state-of-the-(C)ART and the road ahead[J]. Blood Adv, 2023, 7(14)：3350-3360.
|
| 17 |
Lin MJ, Svensson-Arvelund J, Lubitz GS, et al. Cancer vaccines: the next immunotherapy frontier[J]. Nat Cancer, 2022, 3(8)：911-926.
|
| 18 |
Padda J, Khalid K, Zubair U, et al. Chimeric antigen receptor T cell therapy and its significance in multiple myeloma[J]. Cureus, 2021，13(6): e15917.
|
| 19 |
Kegyes D, Constantinescu C, Vrancken L, et al. Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient？[J]. J Hematol Oncol, 2022，15(1)：78.
|
| 20 |
Kleber M, Ntanasis-Stathopoulos I, Terpos E. BCMA in multiple myeloma-a promising key to therapy[J]. J Clin Med, 2021, 10(18)：4088.
|
| 21 |
Baker DJ, Arany Z, Baur JA, et al. CAR T therapy beyond cancer: the evolution of a living drug[J]. Nature, 2023, 619(7971)：707-715.
|
| 22 |
Ali SA, Shi V, Maric I, et al. T cells expressing an anti-B- cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma[J]. Blood, 2016, 128(13)：1688-1700.
|
| 23 |
Brudno JN, Maric I, Hartman SD, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma[J]. J Clin Oncol, 2018，36(22)：2267-2280.
|
| 24 |
Cohen AD, Garfall AL, Stadtmauer EA, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma[J]. J Clin Invest, 2019, 129(6): 2210-2221.
|
| 25 |
Roex G, Timmers M, Wouters K, et al. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma[J]. J Hematol Oncol, 2020, 13(1)：164.
|
| 26 |
Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma[J]. N Engl J Med, 2019，380(18)：1726-1737.
|
| 27 |
Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma[J]. N Engl J Med, 2021，384(8)：705-716.
|
| 28 |
Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma[J]. N Engl J Med, 2023，388(11)：1002-1014.
|
| 29 |
Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CAR-TITUDE-1): a phase 1b/2 open-label study[J]. Lancet，2021，398(10297)：314-324.
|
| 30 |
Cohen AD, Mateos MV, Cohen YC, et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents[J]. Blood, 2023，141(3)：219-230.
|
| 31 |
Mi JQ, Zhao W, Jing H, et al. Phase Ⅱ，open-label study of ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor-t-cell therapy, in Chinese patients with relapsed/refractory multiple myeloma (CAR-TIFAN-1) [J]. J Clin Oncol, 2023，41(6)：1275-1284.
|
| 32 |
Holstein SA, Grant SJ, Wildes TM. Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future[J]. J Clin Oncol, 2023，41(27)：4416-4429.
|
| 33 |
Xu J, Melenhorst JJ. CT103A, a forward step in multiple myeloma immunotherapies[J]. Blood Sci, 2021，3(2)：59-61.
|
| 34 |
Wang D, Wang J, Hu G, et al. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma[J]. Blood, 2021，137(21)：2890-2901.
|
| 35 |
Li CR, Wang D, Song YP, et al. CT103A, a novel fully human BCMA-targeting CAR-T cells, in patients with relapsed/refractory multiple myeloma: Updated results of phase 1b/2 study (FUMANBA-1)[J]. J Clin Oncol, 41(16 suppl): 8025
|
| 36 |
Oliver-Caldés A, González-Calle V, Cabañas V, et al. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CAR-TBCMA-HCB-01): a single-arm, multicentre, academic pilot study[J]. Lancet Oncol, 2023，24(8)：913-924.
|
| 37 |
Han X, Wang Y, Wei J, et al. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy[J]. J Hematol Oncol. 2019，12(1)：128.
|
| 38 |
Zah E, Nam E, Bhuvan V, et al. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma[J]. Nat Commun, 2020，11(1)：2283.
|
| 39 |
Wang Y, Cao J, Gu W, et al. Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma[J]. J Clin Oncol, 2022，40(20)：2246-2256.
|
| 40 |
Mei H, Li C, Jiang H, et al. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma[J]. J Hematol Oncol, 2021，14(1)：161.
|
| 41 |
Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells[J]. Sci Transl Med, 2019, 11(485): eaau7746.
|
| 42 |
Pillarisetti K, Edavettal S, Mendonça M, et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma[J]. Blood, 2020, 135(15): 1232-1243.
|
| 43 |
Mailankody S, Devlin SM, Landa J, et al. GPRC5D-targeted CAR T cells for myeloma[J]. N Engl J Med, 2022，387(13)：1196-1206.
|
| 44 |
Xia J, Li H, Yan Z, et al. Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase Ⅱ Trial[J]. J Clin Oncol, 2023，41(14)：2583-2593.
|
| 45 |
Zhang M, Wei G, Zhou L, et al. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial[J]. Lancet Haematol, 2023，10(2): e107-e116.
|
| 46 |
Li J, Stagg NJ, Johnston J, et al. Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5/CD3 and is a requirement for myeloma cell killing[J]. Cancer Cell, 2017，31(3)：383-395.
|
| 47 |
Jiang D, Huang H, Qin H, et al. Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma[J]. Nat Commun, 2023，14(1)：3642.
|
| 48 |
Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far[J]. Nat Rev Clin Oncol, 2023，20(6)：359-371.
|
| 49 |
Strassl I, Schreder M, Steiner N, et al. The agony of choice-where to place the wave of BCMA-targeted therapies in the multiple myeloma treatment puzzle in 2022 and beyond[J]. Cancers (Basel), 2021，13(18)：4701.
|
| 50 |
Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies[J]. Blood Cancer J, 2021，11(4)：69.
|
| 51 |
Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management[J]. Blood Rev, 2019，34：45-55.
|
| 52 |
Da Vià MC, Dietrich O, Truger M, et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma[J]. Nat Med, 2021, 27(4): 616-619.
|
| 53 |
Wong DP, Roy NK, Zhang K, et al. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers[J]. Nat Commun, 2022，13(1)：217.
|
| 54 |
Xie B, Li Z, Zhou J, et al. Current status and perspectives of dual-targeting chimeric antigen receptor T-cell therapy for the treatment of hematological malignancies[J]. Cancers (Basel)，2022, 14(13): 3230.
|
| 55 |
Choi BD, Yu X, Castano AP, et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity[J]. Nat Biotechnol, 2019，37(9)：1049-1058.
|
| 56 |
Tousley AM, Rotiroti MC, Labanieh L, et al. Co-opting signalling molecules enables logic-gated control of CAR T cells[J]. Nature, 2023，615(7952)：507-516.
|
| 57 |
Li W, Zhang B, Cao W, et al. Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing[J]. Exp Hematol Oncol, 2023，12(1)：44.
|
| 58 |
Pietrobon V, Todd LA, Goswami A, et al. Improving CAR T-cell persistence[J]. Int J Mol Sci, 2021, 22(19)：10828.
|
| 59 |
Wu L, Brzostek J, Sakthi Vale PD, et al. CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance[J]. Cell Rep Med, 2023，4(2)：100917.
|
| 60 |
Roddie C, O′Reilly M, Dias Alves Pinto J, et al. Manufacturing chimeric antigen receptor T cells: issues and challenges[J]. Cytotherapy, 2019，21(3)：327-340.
|
| 61 |
Li X, Dai H, Li X, et al. Optimal model establishment of whole-process management data for CAR-T therapy in China-how should this be done？[J]. Cell Mol Immunol, 2022，19(1)：122-124.
|
| 62 |
Levine BL, Miskin J, Wonnacott K, et al. Global manufacturing of CAR T cell therapy[J]. Mol Ther Methods Clin Dev, 2016，4：92-101.
|
| 63 |
Tyagarajan S, Spencer T, Smith J. Optimizing CAR-T cell manufacturing processes during pivotal clinical trials[J]. Mol Ther Methods Clin Dev, 2019, 16：136-144.
|
| 64 |
Smith TT, Stephan SB, Moffett HF, et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers[J]. Nat Nanotechnol, 2017，12(8)：813-820.
|
| 65 |
Ghassemi S, Durgin JS, Nunez-Cruz S, et al. Rapid manufacturing of non-activated potent CAR T cells[J]. Nat Biomed Eng, 2022, 6(2)：118-128.
|
| 66 |
Wong DP, Roy NK, Zhang K, et al. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers[J]. Nat Commun, 2022, 13(1)：217.
|
| 67 |
Rurik JG, Tombácz I, Yadegari A, et al. CAR T cells produced in vivo to treat cardiac injury [J] Science, 2022，375(6576)：91-96.
|
| 68 |
Zhang J, Hu Y, Yang J, et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL[J]. Nature, 2022, 609(7926)：369-374.
|
| 69 |
Agarwalla P, Ogunnaike EA, Ahn S, et al. Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells[J]. Nat Biotechnol, 2022，40(8)：1250-1258.
|
| 70 |
Zhang DKY, Adu-Berchie K, Iyer S, et al. Enhancing CAR-T cell functionality in a patient-specific manner[J]. Nat Commun, 2023, 14(1)：506.
|
| 71 |
Wu JF, Dhakal B. BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting[J]. J Hematol Oncol, 2023, 16(1)：86.
|
| 72 |
Muthuvel M, Srinivasan H, Louis L, et al. Engineering off-the-shelf universal CAR T cells: a silver lining in the cloud[J]. Cytokine, 2022，156：155920.
|
| 73 |
Mailankody S, Matous JV, Chhabra S, et al. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results[J]. Nat Med，2023, 29(2)：422-429.
|